Back to news

DFW Capital Partners is pleased to announce that its existing portfolio company, Saol Therapeutics, has acquired to acquire three marketed hyperimmune products, WinRho® SDF (Rh0(D) Immune Globulin Intravenous (Human)), HepGam B® (Hepatitis B Immune Globulin Intravenous (Human)) and VARIZIG® (Varicella Zoster Immune Globulin (Human)) from Aptevo Therapeutics Inc. (Nasdaq: APVO). The deal includes both upfront and milestone payments.

Under the terms of a purchase agreement executed by the companies, Saol Therapeutics will acquire the global rights to three hyperimmune products currently marketed by Aptevo: WinRho® SDF for autoimmune platelet disorder and hemolytic disease of the newborn; HepaGam B® for the prevention of Hepatitis B following liver transplantation and for treatment following hepatitis B exposure; and VARIZIG® for treatment following exposure to varicella zoster virus for individuals with compromised immune systems.

“This is a very important day for our company,” said Saol Therapeutics Chief Executive Officer David Penake. “These three products are tremendous strategic fits for us, as we look to build out our orphan business unit. They each have strong clinical value to the patient populations they serve, and we look forward to supporting each product and the clinicians that count on them around the world.”

About DFW Capital Partners

DFW Capital Partners is a private equity investment firm focused on lower middle-market companies. The firm concentrates on service companies, with an emphasis on healthcare and outsourced business and industrial support services. DFW is backed by both institutional and high-net worth individual investors, and has established a 20+ year track record of success in building leading companies. DFW is headquartered in Teaneck, NJ, and maintains an office in Chevy Chase, MD. For more information contact Keith Pennell, Managing Partner, at (201) 836-6000.

Back to news